Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ava Lifescience GmbH operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This prosecution is being conducted by 1 distinct examiner and is situated within 1 distinct art unit. This concentration shows that the company's current patenting efforts are focused on a single technical path, with all activity centralized under one examiner.
RAMADAN, OMAR is the busiest examiner for the portfolio, handling 1 pending office action. Since this is the only pending matter, the examiner's specific interpretation of Biotechnology & Pharmaceuticals standards will be the deciding factor for the company's current filings. For a practitioner, this means there is no examiner diversity to provide varied perspectives, making the specific feedback from RAMADAN, OMAR the primary guide for prosecution.
The involvement of only 1 distinct art unit further emphasizes the singular nature of the current prosecution. Success for Ava Lifescience GmbH depends on navigating the specific technical hurdles presented by the single examiner. With 1 pending office action, the company's immediate patent goals are tied to a single prosecution track, requiring a focused and tailored response to the examiner's requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMADAN, OMAR | 1 | 25.4% | +56.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17435160 | Flow Cytometry Measurement Method and Kit for Carrying Out Same | RAMADAN, OMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17435160 | Flow Cytometry Measurement Method and Kit for Carrying Out Same | RAMADAN, OMAR | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17435160 | Flow Cytometry Measurement Method and Kit for Carrying Out Same | RAMADAN, OMAR | 1678 | §103§112 | Final Rejection | — | Pending | Aug 31, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAva Lifescience GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Omar Ramadan has the most, with 1 of Ava Lifescience GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
